Regentis Secures $7.4M Cash, Over 50% Enrollment in Phase III GelrinC Trial
Regentis Biomaterials ended 2025 with $7.4 million cash and $10 million IPO proceeds, funding its pivotal Phase III GelrinC knee cartilage trial with over 50% patient enrollment across seven new U.S. sites. GelrinC, approved in Europe, will roll out to clinics in 2026 and earned its 27th patent.
1. Financial Results and IPO
Regentis completed its successful December 5, 2025 IPO, raising gross proceeds of $10 million and ending the year with $7.4 million in cash and equivalents. Operating expenses totaled $7.0 million for the year, including $5.3 million of non-cash charges, demonstrating disciplined cash management.
2. Phase III Trial Progress
The company established seven new U.S. clinical sites to support its pivotal Phase III trial for GelrinC, with patient enrollment surpassing 50%. The cash runway is expected to fund site expansion and complete enrollment and treatment by mid-2026.
3. European Commercial Expansion
GelrinC has received regulatory approval in Europe and added six new clinical sites across key markets to build physician adoption. Full clinic rollout is planned in 2026 to create demand and attract commercial partners.
4. Patent and Clinical Milestones
Regentis secured its 27th patent covering the ready-to-use liquid GelrinC formulation, improving production processes. Data published using MOCART assessments showed GelrinC outperformed other treatments and regenerated native-like cartilage structure two years post-treatment.